Significant efficacy of dacomitinib/dacomitinib in non-small cell lung cancer brain metastasis

Although dacomitinib/dacomitinib (Dacomitinib) is not directly called 804, in some communities or professional fields, 804 is often used as an alias or abbreviation for dacomitinib. Dacomitinib, also known as VIZIMPRO, is a tyrosine kinase inhibitor specifically used to treat non-small cell lung cancer. This second-generation EGFR tyrosine kinase inhibitor developed by Pfizer of the United States is famous for its unique irreversible inhibition mechanism.

In theARCHER1050 study, dacomitinib showed longer progression-free survival (PFS) and overall survival compared with gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer. However, the study did not include patients with brain metastases, so the effect of dacomitinib in these patients remains to be determined. Recent studies have been conducted on patients with brain metastases, all of whom have brain metastases with a diameter greater than or equal to 5 mm that have not received radiotherapy. The primary objective of the study was to confirm intracranial objective response rate (iORR).

Research results showed that 46.7% of patients had exon 19 deletion, and 55.3% had exon 21 L858R mutation. The confirmed iORR was as high as 96.7%, and the intracranial complete response rate reached 63.3%. Although the median intracranial PFS (iPFS) has not yet been reached, the 12-month and 18-month iPFS rates remained high at 78.6% and 70.4%, respectively. In a competing risk analysis, the cumulative incidence of intracranial progression within 12 months was only 16.7%. Considering the overall efficacy of intracranial and extracranial lesions, the overall ORR was 96.7%, and the median PFS was 17.5 months. These data fully demonstrate that dacomitinib has a significant intracranial therapeutic effect in patients with brain metastases from EGFR-mutated non-small cell lung cancer.